

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

OVCAR-8

RRID:CVCL_1629

Type: Cell Line

Proper Citation

RRID:CVCL_1629

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1629

Proper Citation: RRID:CVCL_1629

Description: Cell line OVCAR-8 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: High grade ovarian serous adenocarcinoma

Defining Citation: [PMID:1348364](#), [PMID:2041050](#), [PMID:2307530](#), [PMID:3335022](#), [PMID:7718330](#), [PMID:9041185](#), [PMID:9331090](#), [PMID:10700174](#), [PMID:12417041](#), [PMID:12960427](#), [PMID:15748285](#), [PMID:17088437](#), [PMID:19372543](#), [PMID:20164919](#), [PMID:20204287](#), [PMID:21912889](#), [PMID:22068913](#), [PMID:22336246](#), [PMID:22347499](#), [PMID:22384151](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:22628656](#), [PMID:22710073](#), [PMID:23415752](#), [PMID:23839242](#), [PMID:23856246](#), [PMID:23933261](#), [PMID:24023729](#), [PMID:24279929](#), [PMID:24670534](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27235858](#), [PMID:27377824](#), [PMID:27397505](#), [PMID:27807467](#), [PMID:28196595](#), [PMID:28273451](#), [PMID:30485824](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31733513](#), [PMID:31978347](#), [PMID:35839778](#), [PMID:38861359](#)

Comments: Population: Caucasian., Part of: NCI-60 cancer cell line panel., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JFCR39 cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OVCAR-8

Synonyms: OVCAR 8, NIH:OVCAR-8, OVCAR8, OvcAR8, OVCAR.8, OVCA8

Cross References: BTO:BTO_0003054, EFO:EFO_0005444, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:392, BioSample:SAMN03472794, BioSample:SAMN10988023, cancercellines:CVCL_1629, Cell_Model_Passport:SIDM00090, ChEMBL-Cells:ChEMBL3307975, ChEMBL-Targets:ChEMBL612555, CLS:305383, Cosmic:688106, Cosmic:875862, Cosmic:905991, Cosmic:974298, Cosmic:1044242, Cosmic:1092626, Cosmic:1093555, Cosmic:1305315, Cosmic:1312357, Cosmic:1436036, Cosmic:1523764, Cosmic:1526923, Cosmic:1998468, Cosmic:2186582, Cosmic-CLP:905991, DepMap:ACH-000696, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:905991, GEO:GSM2117, GEO:GSM50222, GEO:GSM50286, GEO:GSM185143, GEO:GSM185144, GEO:GSM322534, GEO:GSM322535, GEO:GSM322536, GEO:GSM459646, GEO:GSM459647, GEO:GSM711710, GEO:GSM743477, GEO:GSM743495, GEO:GSM750819, GEO:GSM750831, GEO:GSM784574, GEO:GSM799366, GEO:GSM799429, GEO:GSM844672, GEO:GSM844673, GEO:GSM847109, GEO:GSM851937, GEO:GSM887485, GEO:GSM888566, GEO:GSM1153438, GEO:GSM1181299, GEO:GSM1181339, GEO:GSM1340588, GEO:GSM1341132, GEO:GSM1374803, GEO:GSM1670320, GEO:GSM2124679, GEO:GSM2474994, GEO:GSM2748150, GEO:GSM2748151, GEO:GSM2748152, GEO:GSM2748153, GEO:GSM2748154, GEO:GSM2748155, GEO:GSM3161724, GEO:GSM3161725, IARC_TP53:18079, IARC_TP53:21121, LiGeA:CCLE_464, NCI-DTP:OVCAR-8, PharmacDB:OVCAR8_1220_2019, PRIDE:PXD003539, PRIDE:PXD005942, PRIDE:PXD005946, PRIDE:PXD030304, Progenetix:CVCL_1629, PubChem_Cell_line:CVCL_1629, SKY/M-FISH/CGH:1437, Wikidata:Q54937014

ID: CVCL_1629

Record Creation Time: 20220427T221403+0000

Record Last Update: 20260829T235527+0000

Ratings and Alerts

No rating or validation information has been found for OVCAR-8.

No alerts have been found for OVCAR-8.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 389 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Sheedy AM, et al. (2026) A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer. *Device*, 4(3).

Nathan N, et al. (2026) Tumor-draining lymph nodes in ovarian cancer lack germinal centers but harbor tumor-reactive memory B cells clonally linked to intra-tumoral B cells. *Immunity*, 59(6), 1743.

Qiao M, et al. (2026) ERM Inhibition Confers Ferroptosis Resistance through ROS-Induced NRF2 Signaling. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(16), e13310.

Scholler J, et al. (2026) Engineering a juxtamembrane-targeting CAR T-cell against mesothelin: a novel binder resilient to shed antigen for enhanced efficacy against ovarian and pancreatic cancer. *Frontiers in immunology*, 17, 1805950.

Saleh A, et al. (2026) CCDC80 suppresses high-grade serous ovarian cancer migration via negative regulation of B7-H3. *Molecular oncology*.

Li Y, et al. (2026) Disruption of the SNRPF-DDX24-E2F4 Feedback Loop Uncouples Splicing and Transcriptional Regulation to Suppress Ovarian Cancer Progression. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), e23374.

Zhang Y, et al. (2026) Repression of PRMT activities sensitize human homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatment. *eLife*, 13.

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. *Molecular cancer therapeutics*.

Lobb RJ, et al. (2026) Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. *Cell reports. Medicine*, 7(4), 102694.

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Saini P, et al. (2026) Targeting Interactions Between Siglec-10 and $\alpha 5 \beta 1$ Integrin Enhances Macrophage-Mediated Phagocytosis of Pancreatic Cancer. *Cancer research*, 86(1), 99.

Zeng Z, et al. (2026) Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer. *British journal of cancer*, 134(12), 1830.

Kang Z, et al. (2026) LINE1 RNA demethylation sensitizes cancer cells to PARPi through global chromatin remodeling. *Genome biology*, 27(1).

Lujano-Olazaba O, et al. (2026) RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. *Cell reports*, 45(7), 117650.

Keovilay JA, et al. (2026) Isoquercetin and Zafirlukast Cooperatively Suppress Tumor Growth and Thromboinflammatory Signaling in a Xenograft Model of Ovarian Cancer. *FASEB journal* : official publication of the Federation of American Societies for

Experimental Biology, 40(1), e71361.

Sahm BDB, et al. (2026) Anticancer Potential of Piericidin A1 and Derivatives Isolated From *Streptomyces* sp. Associated With *Palythoa variabilis* From Brazilian Reefs. *Chemistry & biodiversity*, 23(4), e03815.

Meng Y, et al. (2026) IPO9 Promotes Ovarian Cancer Progression by Suppressing HMOX1-Dependent Ferroptosis. *Human mutation*, 2026, 8545131.

Rahman I, et al. (2026) Self-assembled verteporfin nanoparticles decrease drug efflux by P-glycoprotein without light activation in drug-resistant cancer cells. *Bioengineering & translational medicine*, 11(4), e70136.

Plesselova S, et al. (2025) Recapitulating physiologically relevant oxygen levels and extracellular matrix remodeling in patient-derived tumor-immune tunable models reveal targeting opportunities for immunologically cold high-grade serous tumors. *bioRxiv : the preprint server for biology*.

Zhang S, et al. (2025) Vertical inhibition of p110 α /AKT and N-cadherin enhances treatment efficacy in PIK3CA-aberrated ovarian cancer cells. *Molecular oncology*, 19(4), 1132.